Evidence map›Paper›PMID 42494614›Full record

ReviewFrontiers in oncology2026

Beyond AUC: a clinician's guide to building and trusting prediction models in oncology-a narrative review.

Xuexing Wang, Youxian Dou, Yufeng Wang, Kai Sun, Guozhong Zhou

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuexing Wang *Department of Oncology, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Anning, China.
Youxian Dou *Faculty of Medicine, Kunming University of Science and Technology, Kunming, China.
Yufeng WangCadre Medical Department, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Kai SunDepartment of Oncology, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Anning, China.
Guozhong ZhouPain Management Department, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Anning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prediction models are central to advancing precision oncology, yet many fail to translate into clinical practice due to methodological flaws and inadequate validation. This review provides a practical, clinician-oriented guide to the statistical principles and advanced methods for developing, validating, and interpreting robust prediction models. Methods: This narrative review used a targeted literature search of PubMed, Embase, and Web of Science to identify methodological papers, reporting guidelines, and representative oncology prediction model studies, with a focus on literature published between January 1, 2005, and February 28, 2025. Landmark methodological papers published before 2005 were also included when directly relevant. Rather than performing a systematic review or meta-analysis, we synthesized key statistical principles and illustrative examples to guide clinicians and researchers through model development, validation, interpretation, and clinical translation. Findings: A multifaceted evaluation encompassing discrimination, calibration, clinical utility, and external validation is essential for prediction models. Over-reliance on discrimination metrics such as the area under the receiver operating characteristic curve (AUC), while neglecting calibration and clinical utility, can lead to misleading conclusions about a model's value. Rigorous external validation in geographically or temporally distinct cohorts is the most direct test of generalizability, and performance degradation should be interpreted through root-cause analysis rather than treated simply as model failure. Key challenges include managing overfitting, selecting appropriate modeling and validation strategies for different oncology scenarios, addressing special settings such as rare tumors and real-world data, and improving the interpretability of complex "black-box" models. Conclusion: Building a trustworthy prediction model requires a combination of advanced computational methods and rigorous statistical principles. To bridge the gap from model development to clinical impact, researchers must prioritize comprehensive validation, transparent reporting, scenario-appropriate modeling decisions, and critical assessment of a model's real-world utility.

Indexed as

calibrationdecision curve analysisexternal validationmachine learningneoplasmsnomogramsprecision medicine

Identifiers

PMID42494614
PMCPMC13392822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.